JP2003522101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003522101A5 JP2003522101A5 JP2000548337A JP2000548337A JP2003522101A5 JP 2003522101 A5 JP2003522101 A5 JP 2003522101A5 JP 2000548337 A JP2000548337 A JP 2000548337A JP 2000548337 A JP2000548337 A JP 2000548337A JP 2003522101 A5 JP2003522101 A5 JP 2003522101A5
- Authority
- JP
- Japan
- Prior art keywords
- naphthyridine
- formula
- alkyl
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KFAJXZVDBVRZRC-UHFFFAOYSA-N 1,5-naphthyridin-4-amine Chemical compound C1=CN=C2C(N)=CC=NC2=C1 KFAJXZVDBVRZRC-UHFFFAOYSA-N 0.000 description 1
- XQOHGKZCTXPHMB-UHFFFAOYSA-N 1,6-naphthyridin-4-amine Chemical compound C1=NC=C2C(N)=CC=NC2=C1 XQOHGKZCTXPHMB-UHFFFAOYSA-N 0.000 description 1
- PSSPSOSBJIWVGU-UHFFFAOYSA-N 2,8-dichloro-1,5-naphthyridine Chemical compound N1=CC=C(Cl)C2=NC(Cl)=CC=C21 PSSPSOSBJIWVGU-UHFFFAOYSA-N 0.000 description 1
- NWJHKNUMXALBDR-UHFFFAOYSA-N 3,8-dibromo-1,5-naphthyridine Chemical compound BrC1=CC=NC2=CC(Br)=CN=C21 NWJHKNUMXALBDR-UHFFFAOYSA-N 0.000 description 1
- BMNVIIMWNOTDPE-UHFFFAOYSA-N 3,8-dichloro-1,5-naphthyridine Chemical compound ClC1=CC=NC2=CC(Cl)=CN=C21 BMNVIIMWNOTDPE-UHFFFAOYSA-N 0.000 description 1
- FFMPVGXKIJZSQL-UHFFFAOYSA-N 4,5-dichloro-1,6-naphthyridine Chemical compound C1=NC(Cl)=C2C(Cl)=CC=NC2=C1 FFMPVGXKIJZSQL-UHFFFAOYSA-N 0.000 description 1
- DOHYGSCQVQSGBI-UHFFFAOYSA-N 4,8-dibromo-1,6-naphthyridine Chemical compound C1=NC=C2C(Br)=CC=NC2=C1Br DOHYGSCQVQSGBI-UHFFFAOYSA-N 0.000 description 1
- SQLGCTFYLAMNAC-UHFFFAOYSA-N 4,8-dichloro-1,5-naphthyridine Chemical compound C1=CN=C2C(Cl)=CC=NC2=C1Cl SQLGCTFYLAMNAC-UHFFFAOYSA-N 0.000 description 1
- RUZMWDKSPLIZSY-UHFFFAOYSA-N 4-bromo-1,5-naphthyridine Chemical compound C1=CN=C2C(Br)=CC=NC2=C1 RUZMWDKSPLIZSY-UHFFFAOYSA-N 0.000 description 1
- IQPRTBZXSSEENH-UHFFFAOYSA-N 4-bromo-1,6-naphthyridine Chemical compound C1=NC=C2C(Br)=CC=NC2=C1 IQPRTBZXSSEENH-UHFFFAOYSA-N 0.000 description 1
- JECKUINVSSXFNR-UHFFFAOYSA-N 4-chloro-1,5-naphthyridine Chemical compound C1=CN=C2C(Cl)=CC=NC2=C1 JECKUINVSSXFNR-UHFFFAOYSA-N 0.000 description 1
- GKEOOUFCVWEWHA-UHFFFAOYSA-N 4-chloro-1,6-naphthyridine Chemical compound C1=NC=C2C(Cl)=CC=NC2=C1 GKEOOUFCVWEWHA-UHFFFAOYSA-N 0.000 description 1
- GQUGYKURRVQYGU-UHFFFAOYSA-N 4-iodo-1,5-naphthyridine Chemical compound C1=CN=C2C(I)=CC=NC2=C1 GQUGYKURRVQYGU-UHFFFAOYSA-N 0.000 description 1
- 0 Bc1c(*)c(*)c(*)c(*)c1* Chemical compound Bc1c(*)c(*)c(*)c(*)c1* 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9809972.4 | 1998-05-08 | ||
| GB9809988.0 | 1998-05-08 | ||
| GBGB9809988.0A GB9809988D0 (en) | 1998-05-08 | 1998-05-08 | Compounds |
| GBGB9809972.4A GB9809972D0 (en) | 1998-05-08 | 1998-05-08 | Compounds |
| GBGB9903268.2A GB9903268D0 (en) | 1999-02-12 | 1999-02-12 | Compounds |
| GB9903268.2 | 1999-02-12 | ||
| PCT/EP1999/003100 WO1999058533A1 (en) | 1998-05-08 | 1999-05-04 | Phenylurea and phenylthio urea derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003522101A JP2003522101A (ja) | 2003-07-22 |
| JP2003522101A5 true JP2003522101A5 (enExample) | 2006-02-02 |
| JP4633925B2 JP4633925B2 (ja) | 2011-02-16 |
Family
ID=27269308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548337A Expired - Fee Related JP4633925B2 (ja) | 1998-05-08 | 1999-05-04 | フェニル尿素およびフェニルチオ尿素誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6372757B1 (enExample) |
| EP (1) | EP1075478B1 (enExample) |
| JP (1) | JP4633925B2 (enExample) |
| AU (1) | AU4037799A (enExample) |
| CA (1) | CA2331735A1 (enExample) |
| DE (1) | DE69906960T2 (enExample) |
| ES (1) | ES2196806T3 (enExample) |
| WO (1) | WO1999058533A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6093820A (en) | 1997-10-02 | 2000-07-25 | Taro Pharmaceutical Industries Ltd. | Method and reagents for N-alkylating ureides |
| WO2000047576A1 (en) * | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| JP2002536425A (ja) * | 1999-02-12 | 2002-10-29 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | オレキシン受容体アンタゴニストの新規用途 |
| DE60015927T2 (de) | 1999-02-12 | 2005-04-07 | Smithkline Beecham P.L.C., Brentford | Phenylharnstoff und phenylthioharnstoffderivate |
| ES2234840T3 (es) * | 2000-03-14 | 2005-07-01 | Actelion Pharmaceuticals Ltd. | Derivados de 1,2,3,4- tetrahidroisoquinolina. |
| WO2001085693A1 (en) | 2000-05-11 | 2001-11-15 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
| EP1289955B1 (en) * | 2000-06-16 | 2005-04-13 | Smithkline Beecham Plc | Piperidines for use as orexin receptor antagonists |
| US6756379B2 (en) | 2001-07-26 | 2004-06-29 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
| US7683071B2 (en) * | 2000-07-26 | 2010-03-23 | Taro Pharmaceuticals Industries Ltd. | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| US6939873B2 (en) * | 2000-07-26 | 2005-09-06 | Taro Pharmaceuticals Industries Limited | Non-sedating barbituric acid derivatives |
| BR0209334A (pt) | 2001-05-05 | 2004-06-15 | Smithkline Beecham Plc | Aminas n-aroil cìclicas |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0130335D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| JP4498922B2 (ja) | 2002-07-09 | 2010-07-07 | アクテリオン ファーマシューティカルズ リミテッド | ７，８，９，１０−テトラヒドロ−６Ｈ−アゼピノ、６，７，８，９−テトラヒドロ−ピリドおよび２，３−ジヒドロ−２Ｈ−ピロロ［２，１−ｂ］−キナゾリノン誘導体 |
| NZ538749A (en) | 2002-10-11 | 2006-11-30 | Actelion Pharmaceuticals Ltd | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists |
| JP4739760B2 (ja) | 2002-12-11 | 2011-08-03 | タロー・ファーマシューティカル・インダストリーズ・リミテッド | バルビツール酸誘導体を使用する運動障害の治療方法 |
| ATE383345T1 (de) | 2003-04-28 | 2008-01-15 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. |
| US20050032794A1 (en) * | 2003-08-05 | 2005-02-10 | Padia Janak K. | Diamine derivatives of quinone and uses thereof |
| HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| RU2378257C2 (ru) | 2004-03-01 | 2010-01-10 | Актелион Фармасьютиклз Лтд | Замещенные производные 1,2,3,4-тетрагидроизохинолина |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| WO2006003651A2 (en) * | 2004-07-02 | 2006-01-12 | Taro Pharmaceutical Industries, Ltd | A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid |
| US20060178307A1 (en) * | 2005-01-26 | 2006-08-10 | The Regents Of The University Of California | Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP2081576A4 (en) * | 2006-11-14 | 2010-06-30 | Taro Pharmaceuticals North Ame | METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2008001003A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| WO2008143856A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| HRP20120240T1 (hr) | 2007-05-23 | 2012-04-30 | Merck Sharp & Dohme Corp. | Piridil piperidin antagonisti receptora za oreksin |
| JP2011519849A (ja) * | 2008-04-30 | 2011-07-14 | アクテリオン ファーマシューティカルズ リミテッド | ピペリジン及びピロリジン化合物 |
| KR20110091581A (ko) | 2008-12-02 | 2011-08-11 | 글락소 그룹 리미티드 | Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| CN102459229A (zh) | 2009-04-24 | 2012-05-16 | 葛兰素集团有限公司 | 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷 |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| EP2470523A1 (en) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| WO2011031745A1 (en) | 2009-09-09 | 2011-03-17 | Achaogen, Inc. | Antibacterial fluoroquinolone analogs |
| EP2332939A1 (en) | 2009-11-26 | 2011-06-15 | Æterna Zentaris GmbH | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| JP6346862B2 (ja) | 2012-02-07 | 2018-06-20 | エオラス セラピューティクス， インコーポレイテッド | オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン |
| TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
| US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| JP2022534704A (ja) | 2019-06-04 | 2022-08-03 | ヘイガー バイオサイエンシズ，エルエルシー | オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0222839A4 (en) | 1985-05-17 | 1988-11-09 | Univ Australian | ANTI-MALARIA COMPOUNDS. |
| JPH05213884A (ja) * | 1991-06-14 | 1993-08-24 | Upjohn Co:The | 新規な４−アミノキノリン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
| CA2222687A1 (en) | 1995-05-31 | 1996-12-05 | Masami Muraoka | Novel naphthyridine derivatives |
| HUP0100042A3 (en) * | 1996-05-20 | 2003-01-28 | Darwin Discovery Ltd Cambridge | Benzofuran carboxamides medicaments containing the same and their therapeutic use |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
-
1999
- 1999-05-04 CA CA002331735A patent/CA2331735A1/en not_active Abandoned
- 1999-05-04 EP EP99923540A patent/EP1075478B1/en not_active Expired - Lifetime
- 1999-05-04 WO PCT/EP1999/003100 patent/WO1999058533A1/en not_active Ceased
- 1999-05-04 US US09/700,002 patent/US6372757B1/en not_active Expired - Fee Related
- 1999-05-04 JP JP2000548337A patent/JP4633925B2/ja not_active Expired - Fee Related
- 1999-05-04 AU AU40377/99A patent/AU4037799A/en not_active Abandoned
- 1999-05-04 DE DE69906960T patent/DE69906960T2/de not_active Expired - Lifetime
- 1999-05-04 ES ES99923540T patent/ES2196806T3/es not_active Expired - Lifetime